How the US-UK Pharmaceutical Deal Could Transform Patient Access to Life-Saving Medicines

US-UK Drug Deal: A Turning Point for NHS Patient Access

Claims that the recent US-UK pharmaceutical agreement could lead to hundreds of thousands of excess deaths have drawn sharp criticism from healthcare industry leaders, who argue such warnings are both misleading and damaging to patients who stand to benefit from expanded access to new medicines.

Challenging the Alarmist Narrative

Richard Torbett of the Association of the British Pharmaceutical Industry has spoken out against the suggestion that the US-UK drug agreement poses a public health risk. According to Torbett, the analysis underpinning the claim of 229,000 excess deaths in England relies on a heavily criticised modelling methodology for calculating NHS healthcare spending value — and draws on incomplete data to reach its conclusions.

Far from being a threat, Torbett argues the deal reflects a necessary and long-overdue correction to how the NHS evaluates medical innovation.

New Treatments Already Reaching NHS Patients

Within just the past three months, the reformed pricing framework has already delivered tangible results. A range of new medicines — including treatments for multiple cancers, blood disorders, and autoimmune conditions — have been made available to NHS patients that would otherwise have faced significant delays or outright rejection.

This progress has been made possible by an upward revision of the National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold — a benchmark that had remained frozen for nearly 25 years. During that time, the NHS gradually fell behind comparable European nations in providing patients with timely access to innovative treatments, particularly in oncology and rare disease management.

Reframing the Debate Around Patient Benefit

While the need for financially sustainable medicines funding is not in dispute, critics of the deal are being accused of framing a modest policy adjustment as something far more dangerous than the evidence supports. This framing, according to Torbett, overlooks the very real human cost borne by patients who are waiting — or have waited — for access to life-changing therapies.

It also fails to consider the broader economic opportunity the deal presents: the potential to attract greater pharmaceutical investment into the UK, which could in turn generate increased resources for the NHS and fuel the development of the next generation of medical treatments.

Addressing Deep-Rooted Inequities in Medicine Access

Nick Hoile, Senior Director and Chief Operating Officer for Health at MHP Group, echoes this call for a more patient-centred perspective. Government data reveals a stark disparity: for every 100 patients in comparable countries who receive a newly launched medicine within its first year on the market, only 48 patients in the UK receive the same treatment in the same timeframe.

This access gap represents a systemic inequity that the US-UK pharmaceutical deal directly aims to address. Hoile challenges critics of the agreement to put forward credible alternative proposals for how the UK can bring its standard of patient care in line with peer nations — rather than simply opposing reforms that could close this persistent gap.

A Necessary Step Forward

The debate surrounding this deal ultimately centres on a fundamental question: how does the UK balance fiscal responsibility within the NHS against its obligation to provide patients with access to modern, effective treatments? For industry advocates, the answer lies in embracing reforms that reflect the true value of medical innovation — reforms that are already beginning to deliver results for patients across England.